Amy Elazzouzi Sells 1,404 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) SVP Amy Elazzouzi sold 1,404 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total value of $10,881.00. Following the sale, the senior vice president now owns 82,278 shares of the company’s stock, valued at $637,654.50. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Amy Elazzouzi also recently made the following trade(s):

• On Tuesday, January 21st, Amy Elazzouzi sold 1,001 shares of Aura Biosciences stock. The stock was sold at an average price of $7.67, for a total value of $7,677.67.

Aura Biosciences Price Performance

Shares of AURA stock opened at $7.65 on Thursday. Aura Biosciences, Inc. has a fifty-two week low of $6.63 and a fifty-two week high of $12.38. The stock has a market cap of $382.12 million, a P/E ratio of -4.42 and a beta of 0.29. The business has a fifty day simple moving average of $8.02 and a 200-day simple moving average of $8.74.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AURA. Long Focus Capital Management LLC increased its position in shares of Aura Biosciences by 123.9% in the fourth quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock valued at $20,861,000 after buying an additional 1,404,228 shares in the last quarter. Levin Capital Strategies L.P. increased its position in shares of Aura Biosciences by 169.1% in the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock valued at $10,255,000 after buying an additional 783,984 shares in the last quarter. B Group Inc. purchased a new position in shares of Aura Biosciences in the fourth quarter valued at $3,885,000. Franklin Resources Inc. increased its position in shares of Aura Biosciences by 14.8% in the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after buying an additional 215,597 shares in the last quarter. Finally, Ensign Peak Advisors Inc increased its position in shares of Aura Biosciences by 43.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock valued at $3,212,000 after buying an additional 118,000 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on AURA. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research note on Thursday, November 14th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Aura Biosciences has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.